Pulmonary arterial hypertension: Past, present and future;Pulmoner arteryel hipertansiyon: Dünü, bugünü ve yarini

Tuberkuloz ve Toraks

Volumn 58, Issue 1, 2010, Pages 100-107

  Aytekin, Metin ^a   Çaylak, Emrah ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Pathology; Pulmonary arterial hypertension; Treatment

Indexed keywords

BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LUNG HEMODYNAMICS; PATHOGENESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; FORECASTING; HYPERTENSION; HYPERTENSION, PULMONARY; INCIDENCE; PATHOLOGY;

FORECASTING; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; INCIDENCE;

EID: 77951695709     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Palevsky HI, et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80: 1207-1221
2. Pietra GG, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117
4. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: An overview of epidemiology and pathogenesis. Cleve Clin J Med 2003; 70 (Suppl 1): 2-8.
5. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105 (Suppl 2): 37-41.
6. Morse JH, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95: 2603-2606 (Pubitemid 27255485)
7. Loyd JE, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-97
8. Elliott G, et al. Coancestry in apparently sporadic primary pulmonary hypertension. Chest 1995; 108: 973-977
9. Deng Z, et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 2000; 161: 1055-1059
10. Machado RD, et al. A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium. Genomics 2000; 68: 220-228
11. Thomson JR, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745
12. Hyduk A, et al. Pulmonary hypertension surveillance-United States, 1980-2002. Mortality and morbidity weekly report (MMWR). Surveillance Summaries 2005; 54: 1-28.
13. Simonneau G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 5-12.
14. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007; 28: 1-22.
15. Rich S, et al. Primary pulmonary hypertension. A National Prospective study. Ann Intern Med 1987; 107: 216-223
16. Humbert M, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030
17. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431
18. De Marco T. Pulmonary arterial hypertension and women. Cardiol Rev 2006; 14: 312-318
19. Humbert M, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 13-24.
20. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665
21. Newman JH, et al. Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 2004; 43(12 Suppl S): 33-39
22. Christman BW, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75
23. Moncada S, Amezcua JL. Prostacyclin, thromboxane A2 interactions in haemostasis and thrombosis. Haemostasis 1979; 8: 252-265
24. Geraci MW, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999; 103: 1509-1515
25. Tuder RM, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932
26. Stewart DJ, et al. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991;114: 464-469
27. Yanagisawa M, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
28. Giaid A, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739 (Pubitemid 23170122)
29. Rubens C, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569
30. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet 2002; 360: 886-887 (Pubitemid 35472168)
31. Dweik RA. The promise and reality of nitric oxide in the diagnosis and treatment of lung disease. Cleve Clin J Med 2001; 68: 486,88,90,93.
32. Arroliga AC, et al. Primary pulmonary hypertension: Update on pathogenesis and novel therapies. Cleve Clin J Med 2000; 67: 175-8, 151-5, 189-190
33. Kaneko FT, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 917-923
34. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012
35. Kobzik L, et al. Nitric oxide synthase in human and rat lung: Immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 1993; 9: 371-377
36. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221
37. Ozkan M, et al. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001; 179: 233-243 (Pubitemid 34194207)
38. Tuder RM, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285
39. Tuder RM, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-374
40. Tuder RM, Voelkel NF. Plexiform lesion in severe pulmonary hypertension: Association with glomeruloid lesion. Am J Pathol 2001; 159: 382-383
41. Fanburg BL, Lee SL. A new role for an old molecule: Serotonin as a mitogen. Am J Physiol, 1997; 272: 795-806.
42. Lee SL, et al. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266: 46-52.
43. Morrell NW, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104: 790-795
44. Mitchell GF, Pfeffer MA. Pulsatile hemodynamics in hypertension. Curr Opin Cardiol 1999; 14: 361-369
45. Aytekin M, et al. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008.
46. Papakonstantinou E, et al. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 2008.
47. Dresdale DT, Michtom RJ , Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954; 30: 195-207.
48. Nichols WC, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-280
49. Lane KB, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26: 81-84
50. Deng Z, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744
51. Bogdan M, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax 1998; 53: 1059-1062 (Pubitemid 28567008)
52. Herve P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254
53. Shitrit D, et al. Elevation of ELISA d-dimer levels in patients with primary pulmonary hypertension. Respiration 2002; 69: 327-329 (Pubitemid 34920756)
54. Shitrit D, et al. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002; 122: 1674-1678 (Pubitemid 35366081)
55. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784 (Pubitemid 27500070)
56. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322 (Pubitemid 36936846)
57. Yap LB, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-1336 (Pubitemid 39391268)
58. Nagaya N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 60:5.
59. Torbicki A, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848
60. Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
61. Barst RJ, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447
62. Clozel M, et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 867-873
63. Kereveur A, et al. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2233-2239
64. Nagaya N, et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74: 180-4; discussion 184.
65. Nagaya N, et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998; 136: 297-301.
66. Leuchte HH, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764-770
67. Itano N, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 25085-25092
68. McKee CM, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996; 98: 2403-2413
69. Hill AT, et al. Airways inflammation in chronic bronchitis: The effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000; 15: 886-890
70. Maier LA. Clinical approach to chronic beryllium disease and other nonpneumoconiotic interstitial lung diseases. J Thorac Imaging 2002; 17: 273-284
71. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: Mechanisms of action. Arthritis Res Ther 2003; 5: 54-67.
72. Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: The role of innate immunity. Proc Am Thorac Soc 2006; 3: 401-404
73. Voelcker V, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008; 17: 100-107
74. Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair Regen 1999; 7: 79-89.
75. Teder P, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-158
76. Rahmanian M, et al. Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro. Exp Cell Res 1997; 237: 223-230
77. Montesano R, et al. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest 1996; 75: 249-262
78. Itano N, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004; 279: 18679-18687